| __timestamp | Catalyst Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 1860000 |
| Thursday, January 1, 2015 | 8597010 | 2963000 |
| Friday, January 1, 2016 | 7910260 | 6961000 |
| Sunday, January 1, 2017 | 7304399 | 11779000 |
| Monday, January 1, 2018 | 15875961 | 13697000 |
| Tuesday, January 1, 2019 | 36881187 | 15749000 |
| Wednesday, January 1, 2020 | 44233754 | 18638000 |
| Friday, January 1, 2021 | 49628000 | 27196000 |
| Saturday, January 1, 2022 | 58183000 | 31739000 |
| Sunday, January 1, 2023 | 133710000 | 33491000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Catalyst Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. have shown distinct spending patterns over the past decade. From 2014 to 2023, Catalyst Pharmaceuticals increased its SG&A expenses by nearly 2,900%, peaking in 2023. This surge reflects their aggressive market expansion and operational scaling. In contrast, Protagonist Therapeutics exhibited a more conservative growth, with a 1,700% increase over the same period. This suggests a more measured approach, possibly focusing on sustainable growth and targeted investments. The divergence in their spending strategies highlights the varied paths companies can take in the biotech sector, each with its own set of risks and rewards. As these companies continue to evolve, their SG&A strategies will likely play a pivotal role in their future success.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Dr. Reddy's Laboratories Limited vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Catalyst Pharmaceuticals, Inc.
PTC Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: MorphoSys AG vs Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Celldex Therapeutics, Inc.